Alliance Pharma PLC Pre-Close Trading Update (4472C)
19 January 2015 - 6:00PM
UK Regulatory
TIDMAPH
RNS Number : 4472C
Alliance Pharma PLC
19 January 2015
For immediate release 19 January 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Pre-Close Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, announces its pre-close trading update ahead of its
preliminary results for the year ended 31 December 2014.
Turnover for 2014 is expected to be GBP43.5 million (2013:
GBP45.3 million after restatement following the adoption of IFRS
11). Pre-tax profits are expected to be in line with current market
expectations.
Sales of the Hydromol(TM) dermatology range grew 15% year on
year to GBP6.0 million and sales of the stoma care range grew by
10% to GBP4.3 million. Sales of Forceval(TM) recovered from the
issues in 2013 to reach GBP3.5 million (2013: GBP1.9 million). With
unconstrained supplies, sales of Ashton & Parsons Infants'
Powder(TM) reached GBP1.3 million in 2014, up from GBP0.4 million
achieved in 2013. These and other areas of growth were offset by
the expected reduction in toxicology product sales from GBP3.9
million in 2013 to GBP0.1 million in 2014 and the decline in
Nu-Seals(TM) sales from GBP3.1 million to GBP2.5 million as a
result of generic competition in Ireland.
Cash generation remains strong and as a result net bank debt at
31 December 2014 was GBP21.1 million, down GBP4.6 million in the
year. Alliance currently has GBP24 million of committed unutilised
facility available to fund acquisitions. We continue to evaluate a
number of acquisition opportunities.
Alliance's preliminary results for 2014 are due to be announced
on 25 March 2015.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: David
Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to
established niche products and owns or licenses the rights to more
than 60 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSFAFWMFISELF
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024